China's SyMap targets renal denervation with novel 'map-and-ablate' technology

SyMap Medical is developing a selective map-and-ablate technology that has the potential to substantially improve outcom...

March 17, 2022 | Thursday | News
Ping An Good Doctor reports revenue of RMB7,334 Million in 2021

Ping An Healthcare and Technology Company Limited (Ping An Good Doctor) has announced its 2021 annual results. During th...

March 16, 2022 | Wednesday | News
Emerging Trends in Biopharma Deal-Making

Clarivate Plc, a global leader in providing trusted information and insights to accelerate the pace of innovation, ...

March 15, 2022 | Tuesday | News
Adlai Nortye appoints Dr. Victoria Demby as Sr. VP of Global Regulatory Affairs

Adlai Nortye Ltd., a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies,...

March 15, 2022 | Tuesday | News
Chinese startup MediLink Therapeutics closes $70 M Series B financing

MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) has announced completion of a $70million Series B financing. Thi...

March 15, 2022 | Tuesday | News
G-NiiB launches the world’s first anti-viral Gut Microbiome formula in Singapore

GenieBiome (G-NiiB), a biotechnology spin-off of The Chinese University of Hong Kong (CUHK), announces the launch of G-N...

March 15, 2022 | Tuesday | News
China fights against COVID-19 with traditional medicine and comprehensive care

Hong Kong Baptist University (HKBU) has established a transdisciplinary team of experts and supporting personnel to...

March 14, 2022 | Monday | News
Eucure Biopharma starts Phase I trial of YH002 (Anti-OX40 mAb)

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-r...

March 14, 2022 | Monday | News
Impact Therapeutics announces completion of series D1 financing

IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer ther...

March 14, 2022 | Monday | News
Hexvix obtained CDE approval for the inclusion in the clinical real-world evidence pilot study

Asieris Pharmaceuticals, a global innovative biopharma company specializing in discovering and developing innovativ...

March 14, 2022 | Monday | News
Pulnovo Medical appoints Jessie Lian Jia as New CEO

Pulnovo Medical Limited, a globally recognized OTM innovative platform, recently announced the appointment of Jessie Lia...

March 11, 2022 | Friday | News
China's Gan & Lee Pharma begins first-in-human trial for diabetes drug

Chinese firm Gan & Lee Pharmaceuticals has announced that the first subject has been dosed in our Phase I, double-bl...

March 11, 2022 | Friday | News
Hong Kong-based Insilico Medicine focuses on discovery of potential therapeutics for Cystinosis

The MIKADO group, a translational team at the University of Zurich (UZH) focused on generating evidence-driven...

March 10, 2022 | Thursday | News
Hong Kong study finds that smoking increases risk of COVID-19

Researchers from the School of Public Health, LKS Faculty of Medicine of The University of Hong Kong (HKUMed), in collab...

March 9, 2022 | Wednesday | News
China's SeekIn gets CE Mark approval for SeekInCare Pan Cancer early detection test

SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, has announced the CE (Conformit&...

March 8, 2022 | Tuesday | News
China approves phase II trial of Akeso's cancer drug

Akeso, Inc., a biopharmaceutical company dedicated to the development of innovative antibody drugs, has announced that t...

March 8, 2022 | Tuesday | News
WuXi ATU announces launch of TESSA Technology

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabl...

March 8, 2022 | Tuesday | News
Singleron extends reach outside China, strengthens expertise in translational & clinical research

Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platf...

March 8, 2022 | Tuesday | News